Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients and physicians preferences for testing and service delivery

摘要

AimPharmacogenetic studies have identified the presence of the HLA-A*31:01 allele as a predictor of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services.